SCHEDULE 13D/A: BioRestorative Therapies Grants Significant Stock Option to VP of R&D, Boosting Executive's Stake to 15.1%

BioRestorative Therapies, Inc. has granted a substantial stock option to its Vice President of Research and Development, Francisco Silva, increasing his beneficial ownership to approximately 15.1% of the company's common stock.

Summary

• BioRestorative Therapies, Inc. granted Francisco Silva, Vice President of Research and Development, a ten-year option to purchase 768,979 shares of common stock.
• The exercise price for these options is $2.46 per share.
• 50% of the option shares (384,490 shares) became immediately exercisable on the grant date, February 14, 2025.
• The remaining 50% (384,489 shares) will vest in eight nearly equal quarterly installments, commencing one year from the grant date.
• As of February 14, 2025, Francisco Silva beneficially owns 1,196,819 shares of the company's common stock, representing approximately 15.1% of the outstanding shares.
• This beneficial ownership includes 1,028,924 shares issuable upon the exercise of options currently or within 60 days.
• The grant was made under the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan and is intended to qualify as an Incentive Stock Option.

Sentiment

Score: 6

Explanation: The document reports a standard executive compensation event (stock option grant) which is generally neutral but can be seen as slightly positive due to alignment of executive and shareholder interests. There are no overtly negative or positive financial results reported, nor any significant new strategic announcements beyond the compensation.

Positives

• The grant of a significant stock option to the Vice President of Research and Development, Francisco Silva, aligns his interests with those of shareholders, potentially incentivizing long-term performance and retention.
• The vesting schedule, with 50% immediate exercisability and subsequent quarterly vesting, provides both immediate reward and long-term incentive for the executive.

Negatives

• The exercise of these options could lead to a degree of share dilution for existing shareholders, although the impact is spread over time as options vest and are exercised.

Risks

• The document highlights that the ultimate liability for all tax-related items (income tax, social insurance, payroll tax, etc.) related to the option grant, vesting, or exercise remains the participant's responsibility, and the company makes no representation or guarantee regarding tax treatment.
• The company is not obligated to register the shares with the SEC, state securities commissions, or any stock exchange to comply with securities laws, meaning the participant must ensure compliance for any disposition of shares.

Future Outlook

The option grant includes a vesting schedule that extends over three years, with the first quarterly installment vesting one year from the grant date and continuing every three months thereafter until fully vested. This structure incentivizes the Vice President of Research and Development to remain with the company and contribute to its long-term success.

Management Comments

• Robert Kristal, CFO, signed the Incentive Stock Option Award Agreement on behalf of BioRestorative Therapies, Inc.

Industry Context

The granting of stock options to key executives, particularly those in critical roles like Research and Development, is a standard practice across the biotechnology and pharmaceutical industries. It serves as a common mechanism for attracting, retaining, and motivating talent by aligning executive compensation with shareholder value creation. This specific grant is consistent with typical compensation strategies aimed at fostering long-term commitment and performance.

Comparison to Industry Standards

• The grant of a ten-year option with a vesting schedule (50% immediate, remainder quarterly over two years) is a common structure for executive incentive compensation in the biotech sector, comparable to practices at companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals, which often use long-term equity awards to retain top scientific talent.
• The exercise price of $2.46 per share, presumably at or above the market price on the grant date, is typical for incentive stock options, ensuring that the executive benefits from future stock price appreciation.
• The beneficial ownership percentage of 15.1% for a Vice President of Research and Development, while significant, is not unheard of, especially in smaller, development-stage biotech companies where key individuals may hold substantial equity to reflect their critical role and long-term commitment, similar to early-stage executives at companies like Moderna or BioNTech during their formative years.

Corporate Governance

Related Party Transactions

• The grant of a stock option to Francisco Silva, a Vice President of Research and Development, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also potential for increased executive alignment and motivation, which could lead to long-term value creation.
• Employees: The grant to a key executive may signal the company's commitment to retaining top talent and could set a precedent for other employee incentive programs.
• Management: Francisco Silva's increased equity stake provides a strong incentive for him to contribute to the company's success and long-term growth.

Next Steps

• The remaining 384,489 option shares will vest in eight nearly equal quarterly installments, with the first installment vesting on February 14, 2026.
• Francisco Silva may exercise vested options at any time until the expiration date of February 14, 2035, subject to the terms of the agreement and the 2021 Stock Incentive Plan.

Key Dates

Keywords

BioRestorative Therapies, BRTX, Stock Option Grant, Incentive Stock Option, Executive Compensation, SEC Filing, Schedule 13D, Beneficial Ownership, Common Stock, Research and Development, Employee Retention